Zenara Pharma gets CDSCO panel nod to manufacture Covid drug

The approval by the Central Drugs Standard Control Organisation (CDSCO) has been granted under the emergency authorisation route, Zenara Pharma said in a statement.

Published: 28th July 2022 03:10 PM  |   Last Updated: 28th July 2022 03:22 PM   |  A+A-

pills, tablets, medicines

Image used for representational purposes

By PTI

NEW DELHI: Zenara Pharma on Thursday said it has received the CDSCO approval to manufacture and sell combination packs of Nirmatrelvir and Ritonavir tablets, indicated as an option for patients with mild to moderate COVID-19 symptoms.

The approval by the Central Drugs Standard Control Organisation (CDSCO) has been granted under the emergency authorisation route, Zenara Pharma said in a statement.

The tablets will be sold under the brand 'Paxzen' and are being manufactured at the company's USFDA-approved facility in Hyderabad, it added.

The combination pack of Nirmatrelvir and Ritonavir tablets is the generic equivalent of Pfizer's Paxlovid, which has been approved by the United States Food and Drug Administration (USFDA) for COVID-19 treatment, it added.

"We expect to launch Paxzen in the next couple of weeks and are in talks with multiple institutions and several hospitals in India to ensure that the product is readily available for patients in need," Zenara Pharma CEO Srinivas Arutla said.

The company is also likely to tie up with other partners across India to increase patient coverage and has been inviting discussions on the same, Arutla added.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp